Armata's AP-SA02 shows 100% clinical response in Phase 1b/2a S. aureus bacteremia trial

Armata Pharmaceuticals, Inc.

Primary endpoints met: safety, tolerability, and clinical response in ITT (n=50).
AP-SA02 + BAT achieved 100% clinical response at TOC for BAT and EOS vs 75% for placebo (p=0.017).
No treatment-related serious adverse events; two possibly related events (liver enzyme elevation, hypersensitivity).
At day 12, responder rate 88% AP-SA02 vs 58% placebo (p=0.047); MRSA patients had no relapse.
Company plans to initiate a pivotal trial as rapidly as possible.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.